FAST & Fellows Round-Up
Read the latest in FAST and Fellows news:
- On April 27, BridgeBio Pharma announced the launch of Eidos Therapeutics, a CLSI 2016 FAST biopharmaceutical company developing a novel small-molecule treatment for transthyretin (TTR) amyloidosis. BridgeBio has committed $27 million and seasoned R&D executives to advance Eidos’ lead compound, AG10. AG10 was discovered and initially developed by Eidos’ co-founders Isabella Graef, M.D., and Mamoun Alhamadsheh, Ph.D., through research funded by Stanford Medicine’s SPARK program. Read the press release here.
- On April 20, Vyaire Medical, Inc., the healthcare industry’s largest pure-play “breathing” company, announced it has acquired Ciel Medical, Inc., of San Carlos, CA., a 2014 FAST company focused on solving unmet needs of medical professionals caring for intubated patients. Ciel Medical has developed innovative technologies that will strengthen Vyaire’s strategy to offer products that can help reduce the incidence of Ventilator Acquired Pneumonia for ventilated patients. Vyaire management sees the acquisition of Ciel Medical as a step toward the company’s stated goal of becoming the global leader in the respiratory care market. Read the press release here.
- On May 3, Angel Capital Association(ACA), the world’s leading professional association for angel investors, announced the winner of the coveted Luis Villalobos Award at the 2017 ACA Summit in [space] San Francisco. ACA selected Magnetic Insight, a 2015 FAST graduate, as winner of the 2017 Luis Villalobos Award for ingenuity, creativity, and innovation among startups. Based in Alameda, CA, Magnetic Insight has introduced Magnetic Particle Imaging (MPI), the first new diagnostic imaging technique since the introduction of CT, MRI, and PET over 30 years ago.
To learn more about the CLSA Fellows program – the significantly discounted membership for life science startups – click here.
The FAST (Fellows All-Star Team) Accelerator provides select entrepreneurs with intensive team review and coaching to perfect their business model, product development plans, and to build a compelling commercialization strategy. Experienced entrepreneurs, product and business experts (which may include clinical development, regulatory, reimbursement, and business development specialists) will advise selected Fellows during a ten-to-twelve week program, culminating in a Final FAST Showcase to a broad audience that includes potential investors and partners.